Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
Status:
Suspended
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Social cognition impairment is critical to the pathology and morbidity of a number of
psychiatric disorders, including the schizophrenia spectrum, the autism spectrum and the
personality disorders, thus representing a dimension consistent with RDoC. As such, this
study aims to a) further characterize the unique deficits in social cognition (recognition
and interpretation of social cues and representation of thoughts, intentions, and feelings of
others) across disorders, including the schizophrenia spectrum (which includes schizophrenia,
SCZ, schizoaffective disorder, SAD, bipolar disorder, BD, and schizotypal personality
disorder, SPD), the autism spectrum disorders (ASD), and borderline personality disorder
(BPD) compared to healthy controls (HC); b) assess the effect of intranasal oxytocin (OXT) as
a regulator and novel treatment of social cognition impairment in these disorders; and c)
enhance our understanding of the specificity and exact mechanisms of impairment to inform the
accurate dosing of OXT required to modulate social cognition in these disorders and identify
a model of optimum social cognitive function. Addressing these questions will further
catalyze research into a model of optimum social cognitive activity, and accelerate industry
development of agents suited to routine clinical administration.
Phase:
Phase 1
Details
Lead Sponsor:
Maria de las Mercedes Perez Rodriguez
Collaborators:
James J. Peters Veterans Affairs Medical Center VISN 3 Mental Illness Research, Education and Clinical Center